other material
confidence high
sentiment positive
materiality 0.70
Galecto reports positive Phase 2a myelofibrosis data; fibrosis reduction in 6 of 10 evaluable patients
Damora Therapeutics, Inc.
- 6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.
- All 6 patients with fibrosis reduction maintained stable hematological parameters (hemoglobin, WBC, platelets).
- One patient achieved ≥35% spleen volume reduction; two reduced Total Symptom Score >50%; one had anemia response.
- Four patients entered extension due to clinical benefit; one on treatment >30 months; GI adverse events manageable.
- Company will not decide on further GB2064 trials until completion of strategic alternative process.